摘要
直接从人类纤维母细胞生成功能性神经元细胞(诱导神经元细胞)的方法最近已经被开发出来,但到目前为止,此项研究只专注于技术的改进或已知病理表型的再现。一个关键的问题是,这项新技术是否将有助于阐明新的疾病机制或评价治疗的策略。这里我们已经解决了这个问题,通过使用具有未成熟有丝分裂后期谷氨酸神经元细胞特性的人诱导神经元细胞来研究戴萨克斯症(一种典型的溶酶体储存疾病)和Dravet综合症(一种严重的婴儿严重肌阵挛性癫痫)。在戴萨克斯症方面,我们已经成功地表征了典型的神经元病理,GM2神经节苷脂的大量积累,并演示了这种新细胞的培养对未来的药物筛选的适应性。在Dravet综合症方面,我们还鉴定了一个新功能表型,其不被经典的小鼠模型和人体大脑解剖研究所推荐。综上所述,目前的研究表明,人诱导神经元细胞在转化神经科学研究中探索新型疾病机制和评估化合物疗效是有益的。在未来,使用人诱导神经元细胞的研究与良好的基因组蓝图可以集成到多学科以患者为中心的神经障碍研究中去,用以解决新疾病的机制和评估治疗的策略。
关键词: 直接转化,诱导神经元细胞,iN 细胞,溶酶体贮积症,离子通道病;多聚谷氨酰胺疾病
Current Molecular Medicine
Title:Clinical Utility of Neuronal Cells Directly Converted from Fibroblasts of Patients for Neuropsychiatric Disorders: Studies of Lysosomal Storage Diseases and Channelopathy
Volume: 15 Issue: 2
关键词: 直接转化,诱导神经元细胞,iN 细胞,溶酶体贮积症,离子通道病;多聚谷氨酰胺疾病
摘要: Methodologies for generating functional neuronal cells directly from human fibroblasts [induced neuronal (iN) cells] have been recently developed, but the research so far has only focused on technical refinements or recapitulation of known pathological phenotypes. A critical question is whether this novel technology will contribute to elucidation of novel disease mechanisms or evaluation of therapeutic strategies. Here we have addressed this question by studying Tay-Sachs disease, a representative lysosomal storage disease, and Dravet syndrome, a form of severe myoclonic epilepsy in infancy, using human iN cells with feature of immature postmitotic glutamatergic neuronal cells. In Tay-Sachs disease, we have successfully characterized canonical neuronal pathology, massive accumulation of GM2 ganglioside, and demonstrated the suitability of this novel cell culture for future drug screening. In Dravet syndrome, we have identified a novel functional phenotype that was not suggested by studies of classical mouse models and human autopsied brains. Taken together, the present study demonstrates that human iN cells are useful for translational neuroscience research to explore novel disease mechanisms and evaluate therapeutic compounds. In the future, research using human iN cells with well-characterized genomic landscape can be integrated into multidisciplinary patient-oriented research on neuropsychiatric disorders to address novel disease mechanisms and evaluate therapeutic strategies.
Export Options
About this article
Cite this article as:
Clinical Utility of Neuronal Cells Directly Converted from Fibroblasts of Patients for Neuropsychiatric Disorders: Studies of Lysosomal Storage Diseases and Channelopathy, Current Molecular Medicine 2015; 15 (2) . https://dx.doi.org/10.2174/1566524015666150303110300
DOI https://dx.doi.org/10.2174/1566524015666150303110300 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Retigabine: Could it be the Next Broad-Spectrum Antiepileptic Drug?
Current Drug Therapy Editorial [Hot Topic: Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Glutamate as a Modulator of Embryonic and Adult Neurogenesis
Current Topics in Medicinal Chemistry Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology Hematologic Abnormalities in the Antiphospholipid Syndrome
Current Rheumatology Reviews Towards a Unified Theory of Calmodulin Regulation (Calmodulation) of Voltage-Gated Calcium and Sodium Channels
Current Molecular Pharmacology TRPV1 Channel: A Potential Drug Target for Treating Epilepsy
Current Neuropharmacology The Blood-brain Barrier and the Outer Blood-retina Barrier
Medicinal Chemistry Reviews - Online (Discontinued) Cancer Diagnosis and Treatment Guidance: Role of MRI and MRI Probes in the Era of Molecular Imaging
Current Pharmaceutical Biotechnology Dietary Approaches and Supplements in the Prevention of Cognitive Decline and Alzheimer's Disease
Current Pharmaceutical Design Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Unexpected Effects of Acetylcholine Precursors on Pilocarpine Seizure- Induced Neuronal Death
Current Neuropharmacology Functional Interference of Dexamethasone on Some Morphine Effects:Hypothesis for the Steroid-Opioid Interaction
Recent Patents on CNS Drug Discovery (Discontinued) The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Current Status of Complementary and Alternative Medicine in the Treatment of Rheumatic Disease Pain
Current Rheumatology Reviews FMRI in Pediatric Neurodevelopmental Disorders
Current Pediatric Reviews ERRATUM 2
Current Neuropharmacology Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research A Realistic Approach for Anti-Inflammatory, Antinociceptive and Antimutagenic Activities, and Risk Assessment of the Aqueous Extract of <i>Platanus orientalis</i> L. Leaves
Current Molecular Pharmacology Nanomedicines for Brain Targeting: A Patent Review
Recent Patents on Nanomedicine